Gilead Sciences, Inc. (GILD)

68.10
NASDAQ
Prev Close 68.51
Day Low/High 67.92 / 69.17
52 Wk Low/High 60.89 / 85.97
Exchange NASDAQ
Shares Outstanding 1253.72B
Market Cap 85.89B
P/E Ratio 17.57
Div & Yield N.A. (N.A)
The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In

The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In

So far, earnings season has not been the obstacle that many have feared.

Vulnerable Markets, Reopening the Economy, Trading PepsiCo: Market Recon

Vulnerable Markets, Reopening the Economy, Trading PepsiCo: Market Recon

This week the Bureau of Economic Analysis will release its very first estimate for first quarter U.S. economic growth on a quarter over quarter, annualized, and then seasonally adjusted basis.

Nothing Seems to Bother This Market Right Now, Certainly Not Earnings

Nothing Seems to Bother This Market Right Now, Certainly Not Earnings

It is hard to fully understand how the worst economic crisis we have ever seen is not creating more pressure on stocks.

Indian Generic Maker Glenmark Seeks to Make Japanese Covid-19 Drug

Indian Generic Maker Glenmark Seeks to Make Japanese Covid-19 Drug

India's drugmakers aim to manufacture generic versions of any coronavirus 'cure', even before the full findings as to how effective they are.

Saving the Service Economy, Gilead Trials and Intel's Earnings: Market Recon

Saving the Service Economy, Gilead Trials and Intel's Earnings: Market Recon

More government funding is approved to fight Covid-19 layoffs, Gilead sells off on early reports around China trials and Intel announces earnings.

This Sentiment Survey Is Not a Bunch of 'Bull'

This Sentiment Survey Is Not a Bunch of 'Bull'

I have been following this indicator for more than 20 years and have always spent a fair bit of time scoffing at it, but let's look at this one's results.

Keep Your Eyes on Earnings

Keep Your Eyes on Earnings

Overall, the indexes are muddled and clarity is lacking on the economy, but earnings should influence the next major market move.

Cramer: The Stock Market Is Now Divided Into 3 Buckets - And One Is Unfortunate

Cramer: The Stock Market Is Now Divided Into 3 Buckets - And One Is Unfortunate

The problem for index fund owners is they own all three buckets and there are a lot more companies in the third bucket than in the first two.

Takeaways for a Not-so-Great Day

It was another day in which there was some bad news out of Gilead and the bad economic data continues. From my perch, Mr. Market is doing a good job of consolidating a spectacular gain from the mid-March bottom. * Oil +$3.20/barrel. (And energy stoc...

What the Bears Want

In Twitter feeds I can feel the Bears rooting for the markets to go down. (While anything can happen) I am not so sure it's going to happen today - even with the Gilead news. I will end the day longer than I started the day.

Jim Cramer: This Market Values Companies With a Heart

Jim Cramer: This Market Values Companies With a Heart

Brains per share. Hearts Per Share. I've been around long enough to be that positive. I like these companies and more importantly, I like their stocks.

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

How I See Market Performance Evolving Over Time, Trading Advanced Micro

How I See Market Performance Evolving Over Time, Trading Advanced Micro

Will tech continue to trend toward leadership? Who among us can remember when it has not?

Gilead Cut to Market Perform at BMO

The Week Ahead: Jobless Claims, PMI Data and 35 Key Earnings Reports to Watch

The Week Ahead: Jobless Claims, PMI Data and 35 Key Earnings Reports to Watch

More than 450 quarterly reports are on tap, including 105 S&P 500 constituents.

Gilead, Costco and Amazon: 3 Top Pandemic Stocks for DRIP Investors

Gilead, Costco and Amazon: 3 Top Pandemic Stocks for DRIP Investors

Long-term investors must buy during bear markets -- and these companies offer dividend reinvestment or direct investment plans to help seize the opportunity.

Jim Cramer: I'm Very Concerned About a Breakdown in Oil Here

Jim Cramer: I'm Very Concerned About a Breakdown in Oil Here

I have to believe that a few more weeks of lower oil prices and we will see more bankruptcy filings.

We're at a Crossroads and Friday's Close Is Going to Be Huge

We're at a Crossroads and Friday's Close Is Going to Be Huge

Today is about hope on two fronts: the markets and society.

Maintaining Optimism in a Surreal Pandemic Environment

Maintaining Optimism in a Surreal Pandemic Environment

I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.

Gilead Surges on Remdesivir Report: How to Play the Stock Now

Gilead Surges on Remdesivir Report: How to Play the Stock Now

We have a new price target for GILD.

Shorting Apple ($289.75 pre-market trading)

* For investment and placing stock on my Best Ideas List I'll get into the tactical moves I made last night (after the S&P futures rose by nearly +90 handles in response to the Gilead Sciences drug news), but I wanted to mention that I am shorting A...

Less Gold

From early last night - I sold down my position based on "The Smartest Trader" comments that the rise in gold was looking "tired", the reduced reward vs. risk (short term), and because of the positive equity impact on the Gilead drug announcement (a...

Bears Are Capitulating but This Still Is Just a Very Large Counter-Trend Bounce

Bears Are Capitulating but This Still Is Just a Very Large Counter-Trend Bounce

There is likely to be some period of consolidation as market players assess the many crosscurrents that are occurring.

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.

This Market Has Been Rangebound on Derivatives Exposure

This Market Has Been Rangebound on Derivatives Exposure

Friday is the April expiration for S&P 500 index options -- and that can explain more or less why the market has been so tightly pinned.

My New Multi-Group Portfolio Strategy for Trading the Pandemic

My New Multi-Group Portfolio Strategy for Trading the Pandemic

How has my book evolved since the Fed and Treasury rode into town? Here's how.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.

Jim Cramer: Now We're Seeing a Work in Progress

Jim Cramer: Now We're Seeing a Work in Progress

As testing expands, drug trials proceed and tech greats are providing a tracking app, I think we're inching toward going back to work -- and further away from going so low again.